Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma

被引:12
作者
Acevedo, Boris
Perera, Yasser
Torres, Edel
Penton, David
Ayala, Marta
Gavilondo, Jorge
机构
[1] Ctr Genet Engn & Biotechnol, Recombinant Antibodies Labs, Div Pharmaceut, Havana 10600, Cuba
[2] Ctr Genet Engn & Biotechnol, S Spirtius, Cuba
关键词
PSA; PSA purification; monoclonal antibodies;
D O I
10.1002/pros.20267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate specific antigen (PSA) is a relevant antigen in diagnosis; follow-up, and therapeutic approaches for fighting the prostate cancer. Several methods have been published previously to obtain a high purity preparation of PSA. In general, these methods are expensive, time-consuming, laborious, and in some cases produce low yields. METHODS. Based on a panel of 7 anti-PSA Mab's we carried on binding and elution experiments of PSA antigen in 96-well plates. The selected Mab were immobilized in a Sepharose CL-4B activated matrix with the purpose of purify PSA from human seminal fluid. In order to optimize the purification procedure, we test several washing and elution conditions (chaotropic agents, high ionic strength solution, and extreme pH). RESULTS. We selected a high ionic strength solution (2 M MgCl2) as elution condition, and a previous washing step with a mix of two ionic solutions (2.5 M NaCl pH 8/1 M MgCl2 pH 5.5) in order to purify PSA. Using such conditions we obtained a PSA preparation with 90% of purity and 50% of recovery. CONCLUSION. In this article, we report a simple, quickly, and non-expensive procedure to obtain free-PSA from human seminal plasma at high purity levels.
引用
收藏
页码:1029 / 1036
页数:8
相关论文
共 42 条
[1]   Molecular forms of serum prostate-specific antigen - The clinical value of percent free prostate-specific antigen [J].
Abrahamsson, PA ;
Lilja, H ;
Oesterling, JE .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :353-+
[2]   Development and validation of a quantitative ELISA for the measurement of PSA concentration [J].
Acevedo, B ;
Perera, Y ;
Ruiz, M ;
Rojas, G ;
Benítez, J ;
Ayala, M ;
Gavilondo, J .
CLINICA CHIMICA ACTA, 2002, 317 (1-2) :55-63
[3]  
Almagro Isary, 1994, Biotecnologia Aplicada, V11, P175
[4]  
ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181
[5]   Individual prostate-specific antigen (PSA) forms as prostate tumor markers [J].
Becker, C ;
Lilja, H .
CLINICA CHIMICA ACTA, 1997, 257 (01) :117-132
[6]   GENERATION, PURIFICATION, AND CHARACTERIZATION OF A RECOMBINANT SOURCE OF HUMAN PROSTATE-SPECIFIC ANTIGEN [J].
BEI, R ;
PARANAVITANA, C ;
MILENIC, D ;
KASHMIRI, SVS ;
SCHLOM, J .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (04) :261-268
[7]  
Chen ZX, 1997, J UROLOGY, V157, P2166, DOI 10.1016/S0022-5347(01)64704-9
[8]   ENZYMATIC-ACTIVITY OF PROSTATE-SPECIFIC ANTIGEN AND ITS REACTIONS WITH EXTRACELLULAR SERINE PROTEINASE-INHIBITORS [J].
CHRISTENSSON, A ;
LAURELL, CB ;
LILJA, H .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 194 (03) :755-763
[9]   Contamination of purified prostate-specific antigen preparations by kallikrein hK2 [J].
Frenette, G ;
Gervais, Y ;
Tremblay, RR ;
Dubé, JY .
JOURNAL OF UROLOGY, 1998, 159 (04) :1375-1378
[10]  
Habeck LL, 2001, PROSTATE, V46, P298, DOI 10.1002/1097-0045(20010301)46:4<298::AID-PROS1036>3.0.CO